ClinicalTrials.gg
RecruitingNCT06861686Updated Dec 12, 2025

A Modified Baveno Classification of Obstructive Sleep Apnoea Based on Sleepiness and Cardiovascular Scores

An observational study in Obstructive Sleep Apnea (OSA), sponsored by Wissenschaftliches Institut Bethanien e.V. Recruiting at 18 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,800
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Sleep Apnea, Obstructive with a site in Greece — 3 open to participants now, 3 under way, none of them phase 3. Sleep Apnea, Obstructive · Greece.

Started
2025
with 1 other
Observational
8 of 17
3 open now
Registered
16th of 17
by date
Lead sponsor
1 of 17
Wissenschaftliches Institut Bethanien e.V

Among the 17 studies in Sleep Apnea, Obstructive with a site in Greece, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 16th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

3 of the 17 studies in Sleep Apnea, Obstructive with a site in Greece are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Sleep Apnea, Obstructive with a site in Greece, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate a new classification system for obstructive sleep apnoea in patients with newly diagnosed obstructive sleep apnoea and monitor for long-term objective and subjective improvement.

03

Conditions studied

  • Obstructive Sleep Apnea (OSA)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with suspected obstructive sleep apnoea presenting for sleep medical evaluation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patient ≥40 years at the time of signed
  2. Diagnosis of predominant obstructive sleep apnoea with a total apnoea-hypopnoea index of ≥5 /h based on a diagnostic sleep study (polysomnography or polygraphy, as per local standard). Predominant obstructive sleep apnoea defined as ≥70% of respiratory events classified as obstructive.
  3. Signed and dated written informed consent in accordance with ICH-GCP and applicable local regulations

Exclusion criteria

Exclusion criteria

  1. >30% central respiratory events (apnoeas and hypopnoeas) within the diagnostic sleep study
  2. Established sleep apnoea treatment within the last 12 months before study inclusion (positive airway pressure, mandibular advancement device, positional therapy)
  3. Use, or need for chronic use, of any non-invasive positive pressure ventilation device
  4. Participation in an interventional study and/or receiving treatment(s)
  5. Significant disease or condition, which, in the opinion of the investigator, may interfere with study procedures or cause concern regarding the patient's ability to participate in the study
  6. Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the patient an unreliable trial participant)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • weak treatment indication

    Patients with obstructive sleep apnoea (OSA) for whom OSA-specific treatment is generally not recommended according to the Baveno classification

  • intermediate treatment indication

    Patients with obstructive sleep apnoea (OSA) for whom OSA-specific treatment should be considered based on individual assessment according to the Baveno classification

  • strong treatment indication

    Patients with obstructive sleep apnoea (OSA) for whom OSA-specific treatment is generally recommended according to the Baveno classification

06

What researchers measure

Primary outcomes

  1. Change in daytime sleepiness as measured by the Epworth Sleepiness Scale

    The Epworth Sleepiness Scale total score ranges from 0-24. Higher values represent a larger extent of daytime sleepiness

    Time frame: From enrollment to the end of the individual observation period at 36 months

  2. Change in office systolic blood pressure

    Time frame: From enrollment to the end of the individual observation period at 36 months

Secondary outcomes

  1. Change in office diastolic blood pressure

    Time frame: From enrollment to the end of the individual observation period at 36 months

  2. Cardiovascular events (MACE) occurring after study inclusion, including but not limited to myocardial infarction, stroke, hospitalisation for cardiovascular-related treatment (e.g. heart failure, arrhythmia)

    Time frame: From enrollment to the end of the individual observation period at 36 months

  3. Average OSA treatment usage

    Average usage of the prescribed treatment for obstructive sleep apnea, measured as hours per day, derived from therapy device data

    Time frame: From enrollment to the end of the individual observation period at 36 months

  4. Number of patients who discontinue OSA treatment

    Time frame: From enrollment to the end of the individual observation period at 36 months

  5. Change in Insomnia Severity Index total score

    The Insomnia Severity Index (ISI) total score ranges from 0-28. Higher scores represent a larger extent of insomnia-related symptoms. Scores of 15 and above are indicative of clinical insomnia.

    Time frame: From enrollment to the end of the individual observation period at 36 months

  6. Change in subjective sleep length

    Subjective sleep length as assessed via personal interview, measured in hours per night

    Time frame: From enrollment to the end of the individual observation period at 36 months

  7. Change in Fatigue Severity Scale mean score

    The Fatigue Severity Scale (FSS) mean score ranges from 0-7, with higher values indicating a larger extent of fatigue.

    Time frame: From enrollment to the end of the individual observation period at 36 months

  8. Change in cognitive performance as assessed by the Montreal Cognitive Assessment (MoCA) total score

    The Montreal Cognitive Assessment (MoCA) total score ranges from 0-30. A higher score represents a better cognitive performance. A result of 26 or higher is considered normal.

    Time frame: From enrollment to the end of the individual observation period at 36 months

  9. Change in average oxygen desaturation area as measured by overnight oximetry

    The average oxygen desaturation area (unit: s\*%) is automatically calculated from the oximetry signal of a single night poly(somno)graphy. Higher values indicate a larger extent of hypoxic burden.

    Time frame: From enrollment to the end of the individual observation period at 36 months

07

Study locations

12 of 18 sites recruiting
  • Antwerp University Hospital
    Antwerp, Antwerp B-2650, Belgium
    Not yet recruiting
    • Johan Verbraecken, Prof. Dr. · Contactjohan.verbraecken@uza.be · +3238213593
    • Johan Verbraecken, Prof. Dr. · Principal investigator
    • Verena Iven, PhD · Sub investigator
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • Lien Hermans, M.Sc. · Contactlien.hermans@uzleuven.be · +3216348308
    • Dries Testelmans, Prof. Dr. · Principal investigator
    • Alexandros Kalkanis, Prof. Dr. · Sub investigator
  • Centre Hospitalier Universitaire Grenoble Alpes
    Grenoble, Isère 38043 Cedex 9, France
    Not yet recruiting
    • Sébastien Baillieul, Dr. · ContactSbaillieul@chu-grenoble.fr · +33623574355
    • Renaud Tamisier, Prof. Dr. · Principal investigator
    • Jean-Louis Pépin, Dr. · Sub investigator
    • Sébastien Baillieul, Dr. · Sub investigator
  • Wissenschaftliches Institut Bethanien für Pneumologie e.V.
    Solingen, 42699, Germany
    Recruiting
    • Marcel Treml, Dr. · Contactmarcel.treml@klinik-bethanien.de · +49212636661
    • Winfried J Randerath, Prof. Dr. · Principal investigator
    • Sandhya Matthes, Dr. · Sub investigator
  • Department of Pulmonology, University General Hospital of Alexandroupolis, Medical School, Democritus University of Thrace
    Alexandroupoli, Evros 68100, Greece
    Recruiting
    • Savvas Katsaridis, M.Sc. · Contactsavvaskatsaridis@gmail.com · +306981783387
    • Paschalis Steiropoulos, Prof. Dr. · Principal investigator
  • Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School
    Athens, Greece
    Not yet recruiting
    • Georgia Trakada, Prof. Dr. · Contactgtrakada@med.uoa.gr · +306945205079
    • Georgia Trakada, Prof. Dr. · Principal investigator
  • University of Crete
    Heraklion, 71500, Greece
    Recruiting
    • Izolde Bouloukaki, Dr. · Contactizolthi@gmail.com · 00306932978636
    • Sofia E Schiza, Prof. Dr. · Principal investigator
    • Izolde Bouloukaki, Dr. · Sub investigator
  • Respiratory Failure Unit, G. Papanikolaou Hospital
    Thessaloniki, Greece
    Not yet recruiting
  • Istituto Auxologico Italiano
    Milan, 20149, Italy
    Not yet recruiting
    • Elisa Perger, Dr. · Contacte.perger@auxologico.it · +393487727722
    • Carolina Lombardi, Prof. Dr. · Principal investigator
    • Gianfranco Parati, Prof. Dr. · Sub investigator
  • Istituti Clinici Scientifici Maugeri IRCCS
    Pavia, 27100, Italy
    Recruiting
    • Francesco Fanfulla, Dr. · Contactfrancesco.fanfulla@icsmaugeri.it · +390382592010
    • Francesco Fanfulla, Dr. · Principal investigator
    • Carlo Perretti, Dr. · Sub investigator
  • Institute of Tuberculosis and Lung Diseases
    Warsaw, Masovian Voivodeship 01-138, Poland
    Recruiting
    • Paweł Śliwiński, Prof. Dr. · Contactp.sliwinski@wp.pl · +48606623567
    • Paweł Śliwiński, Prof. Dr. · Principal investigator
    • Adam Hołubek, Dr. · Sub investigator
    • Damian Korzybski, Dr. · Sub investigator
    • Malwina Sołtysiak, Dr. · Sub investigator
  • Unidade Local de Saúde de Gaia e Espinho ULSGE - Unidade de Patologia do Sons
    Vila Nova de Gaia, Porto District 4434-502, Portugal
    Recruiting
    • Daniela Ferreira, Dr. · Contactdanisaferreira@gmail.com · +34919400109
    • Daniela Ferreira, Dr. · Principal investigator
    • Daniela Machado, Dr. · Sub investigator
  • Hospital Beatriz Ângelo, Unidade Local de Saúde Loures-Odivelas
    Loures, 2674-514, Portugal
    Recruiting
    • Margarida Aguiar, Dr. · Contactmargarida.aguiar5@gmail.com · +351967933656
    • Margarida Aguiar, Dr. · Principal investigator
    • Margarida Barata, Dr. · Sub investigator
  • Clinica Somnolog
    Bucharest, Romania
    Recruiting
    • Oana Claudia Deleanu, Dr. · Contactoanadeleanu@gmail.com · +40213356910/1415
    • Oana Claudia Deleanu, Dr. · Principal investigator
    • Corina Borcea, Dr. · Sub investigator
    • Andreea Petcu, Dr. · Sub investigator
    • Razvan Lungu, Dr. · Sub investigator
    • Valentin Cosei, Dr. · Sub investigator
  • University of Medicine and Pharmacy Dr. Victor Babes
    Timișoara, Romania
    Recruiting
  • University Clinic of Respiratory and Allergic Diseases Golnik
    Golnik, 4204, Slovenia
    Recruiting
  • Klinik für Pneumologie Universitätsspital Zürich
    Zurich, Switzerland
    Not yet recruiting
    • Esther I Schwarz, Prof. Dr. · Contactestherirene.schwarz@usz.ch · +41442552838
    • Esther I Schwarz, Prof. Dr. · Principal investigator
    • Lara Benning, Dr. med. · Sub investigator
  • Ege University, Faculty of Medicine, Department of Respiratory Medicine
    Izmir, Turkey (Türkiye)
    Recruiting
    • Özen K Basoglu, Prof. Dr. · Contactozen.basoglu@ege.edu.tr · +905326703464
    • Özen K Basoglu, Prof. Dr. · Principal investigator
    • Mehmet S Tasbakan, Prof. Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2030, 60 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 60 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 6, 2025
StartActual
Mar 24, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06861686
Lead sponsor
Wissenschaftliches Institut Bethanien e.V
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Mar 24, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Dec 12, 2025

Study contacts

Marcel Treml, Dr.
Contact
marcel.treml@klinik-bethanien.de
+49212636661
Winfried J Randerath, Prof. Dr.
principal investigator · Wissenschaftliches Institut Bethanien für Pneumologie e.V.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion